Effect of Selective COX-2 Inhibition on Ulcer Healing

• Status: Completed
• Trial end date: 2017-04-12
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the effect of Famotidine plus a COX-2 inhibitor (celecoxib) with Famotidine plus dologesics in ulcer healing in arthritis patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese University of Hong Kong
• Treatments: Celecoxib; Famotidine

Criteria

Inclusion Criteria:

• Gastric ulcers confirmed by endoscopy

• Stop taking NSAIDs for 1 week prior to endoscopy

• Age 18

• H. pylori negative

• Informed written consent

Exclusion Criteria:

• Actively bleeding ulcers

• Ulcers showing dysplasia or malignancy

• Renal failure (serum creatinine >200umol/l)

• Previous gastric surgery

• Moribund or terminal malignancy

• Concomitant use of proton pump inhibitor, misoprostol, aspirin, steroid or anticoagulant